Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2014 Apr;34(4):1609-15.

The addition of a pregnenolone pendant group enhances the anticancer properties of titanocene dichloride in a mcf-7 xenograft model.

Author information

1
Department of Biology, University of Puerto Rico - Reciento Rio Piedras, PO Box 23360, San Juan, Puerto Rico 00931. valancew@gmail.com.

Abstract

BACKGROUND/AIM:

Titanocene dichloride held great promise as a chemotherapeutic compound in pre-clinical studies. However, subsequent clinical trials revealed hepatoxicity and nephrotoxicity, which limited its use in clinical applications. Therefore, we used steroid pendant groups to improve the targeting of titanocene in MCF-7 breast cancer cells, and demonstrated a 10-fold lower effective dose compared to titanocene in in vitro assays. The aim of the present study was to test the efficacy of a titanocene functionalized with pregnenolone (Ti-Preg) in an in vivo breast cancer model.

MATERIALS AND METHODS:

Xenografts from the MCF7 breast cancer cell line were implanted into athymic nu/nu mice to evaluate the potential of Ti-Preg as an anti-breast cancer agent.

RESULTS:

Ti-Preg demonstrated significant inhibition of MCF-7 tumor growth when compared to vehicle and to titanocene controls.

CONCLUSION:

Our findings demonstrate the potential of steroid pendent groups for targeting chemotherapeutics to steroid hormone-dependent cancer.

KEYWORDS:

TLT-1; Titanocene; breast cancer; steroid pendant groups; titanocenyl-pregnenolone

PMID:
24692689
PMCID:
PMC4053690
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Support Center